​

Poseida Therapeutics (PSTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

PSTX Stock Forecast

Poseida Therapeutics (PSTX) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $12.50, with a high of $15.00 and a low of $10.00. This represents a 31.58% increase from the last price of $9.50.

- $3 $6 $9 $12 $15 High: $15 Avg: $12.5 Low: $10 Last Closed Price: $9.5

PSTX Stock Rating

Poseida Therapeutics stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (50.00%), 3 Hold (50.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 0 3 3 Strong Sell Sell Hold Buy Strong Buy

PSTX Price Target Upside V Benchmarks

TypeNameUpside
StockPoseida Therapeutics31.58%
SectorHealthcare Stocks 18.80%
IndustryBiotech Stocks 54.28%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$10.00
Last Closing Price$9.50$9.50$9.50
Upside/Downside--5.26%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25--5--5
Dec, 241-5--6
Nov, 24234--9
Oct, 2423---5
Sep, 2423---5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 02, 2024Edward TenthoffPiper Sandler$10.00$9.317.41%5.26%
Jan 04, 2023H.C. Wainwright$15.00$5.79159.07%57.89%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 02, 2024Piper SandlerOverweightNeutraldowngrade
Oct 17, 2024H.C. WainwrightBuyBuyhold
Aug 09, 2022Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.07$-0.89------
Avg Forecast$-2.29$-0.47$-1.50$-0.73$-1.82$-1.81$-1.17$0.23
High Forecast$-1.61$-0.45$-1.27$-0.62$-1.78$-1.60$-0.65$0.30
Low Forecast$-2.93$-0.49$-1.62$-0.82$-1.85$-2.02$-1.50$0.13
Surprise %-103.06%89.36%------

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$31.24K$130.36M$64.70M-----
Avg Forecast$27.50M$173.47M$46.35M$147.12M$43.33M$44.00M$76.51M$379.38M
High Forecast$33.32M$180.79M$52.57M$154.54M$52.81M$53.62M$93.25M$462.37M
Low Forecast$21.21M$168.23M$40.14M$139.71M$28.44M$28.87M$50.21M$248.97M
Surprise %-99.89%-24.85%39.58%-----

Net Income Forecast

$-300M $-230M $-160M $-90M $-20M $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.40M$-64.00M$-123.43M-----
Avg Forecast$-206.88M$-42.11M$-123.43M$-60.76M$-163.84M$-163.24M$-96.94M$20.74M
High Forecast$-145.35M$-40.46M$-114.54M$-56.17M$-160.65M$-144.65M$-58.36M$26.64M
Low Forecast$-263.84M$-44.43M$-146.10M$-74.05M$-167.02M$-181.82M$-135.52M$11.47M
Surprise %-102.13%51.97%------

PSTX Forecast FAQ

Is Poseida Therapeutics stock a buy?

Poseida Therapeutics stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Poseida Therapeutics is a favorable investment for most analysts.

What is Poseida Therapeutics's price target?

Poseida Therapeutics's price target, set by 6 Wall Street analysts, averages $12.5 over the next 12 months. The price target range spans from $10 at the low end to $15 at the high end, suggesting a potential 31.58% change from the previous closing price of $9.5.

How does Poseida Therapeutics stock forecast compare to its benchmarks?

Poseida Therapeutics's stock forecast shows a 31.58% upside, outperforming the average forecast for the healthcare stocks sector (18.80%) and underperforming the biotech stocks industry (54.28%).

What is the breakdown of analyst ratings for Poseida Therapeutics over the past three months?

  • January 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 16.67% Strong Buy, 0% Buy, 83.33% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 22.22% Strong Buy, 33.33% Buy, 44.44% Hold, 0% Sell, 0% Strong Sell.

What is Poseida Therapeutics’s EPS forecast?

Poseida Therapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.73, marking a 0% decrease from the reported $0 in 2023. Estimates for the following years are $-1.82 in 2025, $-1.81 in 2026, $-1.17 in 2027, and $0.23 in 2028.

What is Poseida Therapeutics’s revenue forecast?

Poseida Therapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $147.12M, reflecting a 127.38% increase from the reported $64.7M in 2023. The forecast for 2025 is $43.33M, followed by $44M for 2026, $76.51M for 2027, and $379.38M for 2028.

What is Poseida Therapeutics’s net income forecast?

Poseida Therapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-60.759M, representing a -50.77% decrease from the reported $-123M in 2023. Projections indicate $-164M in 2025, $-163M in 2026, $-96.944M in 2027, and $20.74M in 2028.